Dapsone is an anticatalysis for Alzheimer's disease exacerbation

Jong Hoon Lee; Badar Kanwar; Chul Joong Lee; Consolato Sergi; Michael D. Coleman

doi:10.1016/j.isci.2022.104274

Dapsone is an anticatalysis for Alzheimer's disease exacerbation

Jong Hoon Lee^*
, Badar Kanwar
, Chul Joong Lee
, Consolato Sergi
, Michael D. Coleman

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

11 Citations (SciVal)

15 Downloads (Pure)

Abstract

Brain inflammation generally accelerates neurodegeneration. Alzheimer's disease (AD) triggers an innate immune response by activating a cytosolic DNA sensor cyclic-GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathway. Our study investigated patients with leprosy and AD. They were treated with dapsone (4,4′-diaminodiphenyl sulfone, DDS) as a neuroinflammasome competitor and cGAS/STING pathway inhibitor. Four groups were defined: Treatment (T) 1: DDS prescribed AD diagnosed, T 2: DDS prescribed AD undiagnosed, T 3 DDS unprescribed AD diagnosed, and T 4: DDS unprescribed AD undiagnosed. Dapsone effects on AD can be clearly distinguished according to dapsone presence or absence. T1:T3 proved that the incidence of AD was significantly reduced by dapsone. T2:T3 proved that the prevalence of AD was significantly high without dapsone. T1:T4 proved that the prevalence decreased when taking dapsone. Our study demonstrates that dapsone can prevent AD exacerbation and may represent a preventive therapeutic option for exacerbated AD.

Original language	English
Article number	104274
Journal	iScience
Volume	25
Issue number	5
Early online date	20 Apr 2022
DOIs	https://doi.org/10.1016/j.isci.2022.104274
Publication status	Published - 20 May 2022

Bibliographical note

Funding

We thank Sorokdo National Hospital and the Ministry of Health and Welfare for collecting research data. In addition, we thank Sister Marianne Stoeger, who worked at a hospital in Innsbruck, who joined Sorok Island in February 1962 and Sister Margaritha Pissarek entered Sorok Island in October 1967. They treated the control group of this study for 40 years with dedication, free of charge, and we decided to call this AD study 'Marianne and Margaritha treatment'. JL's older sister, Young Soo Lee, a genius painter and designer, who has shown improvement in cognitive function in dementia for 10 years even after undergoing cerebral hemorrhage, CPR, and two surgeries, who have been the constant motivation for this study and the thesis. Six hours before we heard from the editorial office, we heard that she had passed away. She repainted her pictures and read books. Conceptualization, J.L.; Methodology, J.L.; Investigation, B.K. C.J.L, and J.L.; Resources, C.J.L. and J.L.; Data Curation, J.L.; Writing ? Original Draft, J.L.; Writing ? Review & Editing, C.S. and M.D.C.; Visualization, J.L.; Supervision, B.K. C.J.L, C.S. and M.D.C.; Project Administration, J.L. The authors declare no competing interests.

Keywords

Biological sciences
Clinical neuroscience
Health sciences
Neuroscience

Access to Document

10.1016/j.isci.2022.104274Licence: CC BY-NC-ND 4.0

Dapsone is an anticatalysis for Alzheimer’s disease exacerbation
© 2022 The Authors. This is an open access article under the CC BY-NC-ND license 4.0
Final published version, 3.11 MBLicence: CC BY-NC-ND 4.0

Cite this

@article{3707a29bb2304fe4ab6145a137e3c1f3,

title = "Dapsone is an anticatalysis for Alzheimer's disease exacerbation",

abstract = "Brain inflammation generally accelerates neurodegeneration. Alzheimer's disease (AD) triggers an innate immune response by activating a cytosolic DNA sensor cyclic-GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathway. Our study investigated patients with leprosy and AD. They were treated with dapsone (4,4′-diaminodiphenyl sulfone, DDS) as a neuroinflammasome competitor and cGAS/STING pathway inhibitor. Four groups were defined: Treatment (T) 1: DDS prescribed AD diagnosed, T 2: DDS prescribed AD undiagnosed, T 3 DDS unprescribed AD diagnosed, and T 4: DDS unprescribed AD undiagnosed. Dapsone effects on AD can be clearly distinguished according to dapsone presence or absence. T1:T3 proved that the incidence of AD was significantly reduced by dapsone. T2:T3 proved that the prevalence of AD was significantly high without dapsone. T1:T4 proved that the prevalence decreased when taking dapsone. Our study demonstrates that dapsone can prevent AD exacerbation and may represent a preventive therapeutic option for exacerbated AD.",

keywords = "Biological sciences, Clinical neuroscience, Health sciences, Neuroscience",

author = "Lee, \{Jong Hoon\} and Badar Kanwar and Lee, \{Chul Joong\} and Consolato Sergi and Coleman, \{Michael D.\}",

note = "{\textcopyright} 2022 The Authors. This is an open access article under the CC BY-NC-ND license 4.0 ",

year = "2022",

month = may,

day = "20",

doi = "10.1016/j.isci.2022.104274",

language = "English",

volume = "25",

journal = "iScience",

issn = "2589-0042",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Dapsone is an anticatalysis for Alzheimer's disease exacerbation

AU - Lee, Jong Hoon

AU - Kanwar, Badar

AU - Lee, Chul Joong

AU - Sergi, Consolato

AU - Coleman, Michael D.

PY - 2022/5/20

Y1 - 2022/5/20

N2 - Brain inflammation generally accelerates neurodegeneration. Alzheimer's disease (AD) triggers an innate immune response by activating a cytosolic DNA sensor cyclic-GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathway. Our study investigated patients with leprosy and AD. They were treated with dapsone (4,4′-diaminodiphenyl sulfone, DDS) as a neuroinflammasome competitor and cGAS/STING pathway inhibitor. Four groups were defined: Treatment (T) 1: DDS prescribed AD diagnosed, T 2: DDS prescribed AD undiagnosed, T 3 DDS unprescribed AD diagnosed, and T 4: DDS unprescribed AD undiagnosed. Dapsone effects on AD can be clearly distinguished according to dapsone presence or absence. T1:T3 proved that the incidence of AD was significantly reduced by dapsone. T2:T3 proved that the prevalence of AD was significantly high without dapsone. T1:T4 proved that the prevalence decreased when taking dapsone. Our study demonstrates that dapsone can prevent AD exacerbation and may represent a preventive therapeutic option for exacerbated AD.

AB - Brain inflammation generally accelerates neurodegeneration. Alzheimer's disease (AD) triggers an innate immune response by activating a cytosolic DNA sensor cyclic-GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathway. Our study investigated patients with leprosy and AD. They were treated with dapsone (4,4′-diaminodiphenyl sulfone, DDS) as a neuroinflammasome competitor and cGAS/STING pathway inhibitor. Four groups were defined: Treatment (T) 1: DDS prescribed AD diagnosed, T 2: DDS prescribed AD undiagnosed, T 3 DDS unprescribed AD diagnosed, and T 4: DDS unprescribed AD undiagnosed. Dapsone effects on AD can be clearly distinguished according to dapsone presence or absence. T1:T3 proved that the incidence of AD was significantly reduced by dapsone. T2:T3 proved that the prevalence of AD was significantly high without dapsone. T1:T4 proved that the prevalence decreased when taking dapsone. Our study demonstrates that dapsone can prevent AD exacerbation and may represent a preventive therapeutic option for exacerbated AD.

KW - Biological sciences

KW - Clinical neuroscience

KW - Health sciences

KW - Neuroscience

UR - https://www.scopus.com/pages/publications/85129475992

UR - https://www.sciencedirect.com/science/article/pii/S2589004222005442

U2 - 10.1016/j.isci.2022.104274

DO - 10.1016/j.isci.2022.104274

M3 - Article

AN - SCOPUS:85129475992

SN - 2589-0042

VL - 25

JO - iScience

JF - iScience

IS - 5

M1 - 104274

ER -

Dapsone is an anticatalysis for Alzheimer's disease exacerbation

Abstract

Bibliographical note

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this